FCMV
Foresite Capital Management VI Portfolio holdings
AUM
$178M
This Quarter Return
-15.51%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$183M
AUM Growth
+$183M
(-19%)
Cap. Flow
+$0
Cap. Flow
% of AUM
0%
Top 10 Holdings %
Top 10 Hldgs %
93.59%
Holding
14
New
–
Increased
–
Reduced
–
Closed
–
Top Buys
No buys this quarter
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $54.4M | 29.8% | 2,221,474 | – | – |
|
|
ALMS
2
Alumis Inc. Common Stock
ALMS
$479M
| $25.8M | 14.14% | 4,202,670 | – | – |
|
|
CNTA
3
Centessa Pharmaceuticals
CNTA
$2.25B
| $18M | 9.87% | 1,253,379 | – | – |
|
4
RAPT Therapeutics
RAPT
$188M
| $15.3M | 8.35% | 12,500,000 | – | – |
|
5
Akero Therapeutics
AKRO
$3.74B
| $14.8M | 8.09% | 365,000 | – | – |
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $12.9M | 7.05% | 585,000 | – | – |
|
|
BCAX
7
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $12.4M | 6.78% | 950,000 | – | – |
|
8
Structure Therapeutics
GPCR
$1.11B
| $7.27M | 3.98% | 420,000 | – | – |
|
9
Allogene Therapeutics
ALLO
$251M
| $5.03M | 2.76% | 3,448,275 | – | – |
|
10
Corvus Pharmaceuticals
CRVS
$428M
| $5.03M | 2.75% | 1,581,233 | – | – |
|
11
Cullinan Oncology
CGEM
$445M
| $4.8M | 2.63% | 634,558 | – | – |
|
12
Kymera Therapeutics
KYMR
$2.95B
| $4.01M | 2.19% | 146,332 | – | – |
|
13
CASI Pharmaceuticals
CASI
$35.8M
| $2.87M | 1.57% | 1,329,383 | – | – |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $26.6K | 0.01% | 1,974 | – | – |
|